EXEL:NASDAQ
Exelixis Inc
$56.12
arrow_downward
-2.28%(-1.31) 1D
$56.12
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$56.76
High
$57.43
Low
$54.54
Mkt. cap
13.91B
Avg. vol.
2.50M
Volume
2.88M
P/E ratio
17.63
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
Open
$56.76
High
$57.43
Low
$54.54
Mkt. cap
13.91B
Avg. vol.
2.50M
Volume
2.88M
P/E ratio
17.63
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
Stocktwits
·
52 minutes ago
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
Benzinga
·
3 hours ago
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Investor's Business Daily
·
7 hours ago
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug
Yahoo Finance
·
7 hours ago
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com